K
Kirsty Thomson
Researcher at University College London Hospitals NHS Foundation Trust
Publications - 119
Citations - 5386
Kirsty Thomson is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Transplantation & Alemtuzumab. The author has an hindex of 36, co-authored 118 publications receiving 4766 citations. Previous affiliations of Kirsty Thomson include University College Hospital & Imperial College London.
Papers
More filters
Journal ArticleDOI
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W. Ng,Nikhil Faulkner,Georgina H. Cornish,Annachiara Rosa,Ruth Harvey,Saira Hussain,Rachel Ulferts,Christopher Earl,A.G. Wrobel,D.J. Benton,Chloe Roustan,William Bolland,Rachael Thompson,Ana Agua-Doce,Philip Hobson,Judith Heaney,Hannah Rickman,Stavroula Paraskevopoulou,Catherine F Houlihan,Kirsty Thomson,Emilie Sanchez,Gee Yen Shin,Moira J. Spyer,Dhira Joshi,Nicola O’Reilly,Philip A. Walker,Svend Kjaer,Andrew Riddell,Catherine Moore,Bethany R. Jebson,Meredyth G. Ll Wilkinson,Lucy R. Marshall,Elizabeth C. Rosser,Anna Radziszewska,Hannah Peckham,Coziana Ciurtin,Lucy R. Wedderburn,Rupert Beale,Charles Swanton,Sonia Gandhi,Brigitta Stockinger,John W. McCauley,Steve Gamblin,Laura E. McCoy,Peter Cherepanov,Eleni Nastouli,George Kassiotis,George Kassiotis +47 more
TL;DR: Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, preexisting humoral immunity was detected and antibodies targeting the S2 subunit were particularly prevalent in children and adolescents.
Journal ArticleDOI
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
Emma C. Morris,Kirsty Thomson,Kirsty Thomson,Charles Craddock,Charles Craddock,Prem Mahendra,Prem Mahendra,Donald Milligan,Donald Milligan,Gordon Cook,Gordon Cook,Graeme M. Smith,Graeme M. Smith,Anne Parker,Anne Parker,Steve Schey,Steve Schey,Rajesh Chopra,Rajesh Chopra,C Hatton,C Hatton,Jane Tighe,Jane Tighe,Anne Hunter,Anne Hunter,Karl S. Peggs,Karl S. Peggs,David C. Linch,David C. Linch,Anthony H. Goldstone,Anthony H. Goldstone,Stephen Mackinnon,Stephen Mackinnon +32 more
TL;DR: Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable.
Journal ArticleDOI
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
Karl S. Peggs,Ann Hunter,Rajesh Chopra,Anne Parker,Premini Mahendra,Donald Milligan,Charles Craddock,Ruth Pettengell,Ahmet Dogan,Kirsty Thomson,Emma C. Morris,Geoff Hale,Herman Waldmann,Anthony H. Goldstone,David C. Linch,Stephen Mackinnon +15 more
TL;DR: Data show the potential for durable responses in patients who have previously had substantial treatment for Hodgkin's lymphoma, and the low non-relapse-related mortality suggests the procedure could be undertaken earlier in the course of the disease.
Journal ArticleDOI
Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation
Karl S. Peggs,Kirsty Thomson,Edward R. Samuel,Gemma Dyer,Julie Armoogum,Ronjon Chakraverty,Kwok Pang,Stephen Mackinnon,Mark W. Lowdell +8 more
TL;DR: The ability of cytomegalovirus-specific T cells, directly isolated from donor leucapheresates on the basis of interferon γ secretion, to restore antiviral immunity in a group of 25 patients following related-donor transplantation is investigated in a single-arm phase I-II study.
Journal ArticleDOI
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.
Karl S. Peggs,Kirsty Thomson,Daniel P. Hart,J Geary,Emma C. Morris,Kwee Yong,Anthony H. Goldstone,David C. Linch,Stephen Mackinnon +8 more
TL;DR: The results of dose-escalating DLIs in 46 patients undergoing RIT indicate that DLI may be associated with a significantly increased toxicity in unrelated compared to sibling donor transplant recipients receiving identical treatment protocols and support the presence of clinically relevant graft-versus-Hodgkin activity.